Introduction {#Sec1}
============

The increasing prevalence of obesity has transformed surgical practice and the efficacy of bariatric surgery in aiding weight loss \[[@CR1], [@CR2]\]. The long-term health benefits of reducing weight have been well studied \[[@CR3]\]. Remission of diabetes mellitus (DM) is often cited as an indication for bariatric surgery, with multiple studies indicating promising use of bariatric surgery for this purpose \[[@CR4], [@CR5]\]. Nevertheless, there may be some concerns about the safety of bariatric surgery in diabetic patients since DM has been associated with increased perioperative complications including anastomotic leak as well as mortality \[[@CR6], [@CR7]\]. This does not seem to be a consistent finding as some studies have failed to demonstrate that increased risk \[[@CR8], [@CR9]\]. Furthermore, there is paucity of literature on the differences in perioperative outcomes in diabetics who require insulin therapy compared with those who do not. Our aim was to evaluate perioperative outcomes in diabetic patients undergoing laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB), the two most common bariatric procedures. We hypothesize that patients with DM will have a higher perioperative complication rate especially those requiring preoperative insulin therapy.

Materials and Methods {#Sec2}
=====================

Population and Study Groups {#Sec3}
---------------------------

This retrospective study used the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database which was used to identify patients who underwent LSG (Current Procedural Terminology code 43775) and LRYGB (Current Procedural Terminology code 43644) between January 1, 2015, and December 31, 2017. The MBSAQIP registry includes data from nationally accredited bariatric centers in North America. This database study was ruled exempt from Institutional Review Board approval at our institution.

Only procedures performed by conventional laparoscopic approach were included. Exclusion criteria included age less than 18 years, conversion/revision procedures, robotic-assisted or open cases, unplanned conversion to alternative approaches, emergent cases, and cases with missing data. A total of 352,440 patients met the criteria above. There were 15,513 patients (4.4%) with missing 30-day follow-up. Thus, the total number of patients analyzed was 336,927. Patients were grouped based on diabetic status: non-diabetics (NDM); non-insulin-dependent DM (NIDDM), defined as those with a preoperative diagnosis of DM requiring therapy with a non-insulin anti-diabetic agent; and insulin-dependent DM (IDDM), defined as those with a preoperative diagnosis of DM requiring daily insulin therapy.

Covariates related to patient demographics included age, sex, race, preoperative body mass index (BMI) closest to surgery, and American Society of Anesthesiologists (ASA) class. Relevant patient comorbidities included in the analysis were coronary artery disease, hypertension, hyperlipidemia, smoking history, chronic obstructive pulmonary disease, oxygen dependence, obstructive sleep apnea, renal insufficiency, dialysis, deep vein thrombosis, pulmonary embolism, preoperative anticoagulation, inferior vena cava filter in place, steroid use, previous obesity/foregut surgery, use of an assistive device for ambulation, and functional status.

Outcome Measures {#Sec4}
----------------

The primary outcomes of interest within 30 days of the operation were the occurrence of serious adverse events, readmission, reoperation, and mortality. Serious adverse events was a composite outcome that included at least one of the following: acute renal failure requiring dialysis, progressive renal insufficiency, cardiac arrest, myocardial infarction, unplanned admission to the intensive care unit, coma greater than 24 h, cerebrovascular accident, ventilator use for more than 48 h, unplanned intubation, pneumonia, surgical site infection (superficial, deep/incisional, or organ space), sepsis, septic shock, urinary tract infection, deep vein thrombosis, pulmonary embolism, anticoagulation for blood clot, bleeding requiring a transfusion, any intervention within 30 days, drain present at 30 days, and wound disruption.

Secondary outcomes evaluated included length of stay greater than 2 days, renal events (acute renal failure requiring dialysis or progressive renal insufficiency), cardiac events (cardiac arrest or myocardial infarction), respiratory complications (ventilator for more than 48 h, unplanned intubation, or pneumonia), surgical site infection (superficial, deep/incisional, or organ space), septic events (sepsis or septic shock), urinary tract infections, venous thromboembolic (VTE) events (deep vein thrombosis, pulmonary embolism, or anticoagulation for presumed blood clot), transfusion for bleeding within 72 h, and reintervention within 30 days. The causes of mortality for each patient cohort were reported.

Outcomes present at the time of surgery such as surgical site infections (superficial, deep/incisional, and organ space), sepsis, septic shock, pneumonia, urinary tract infections, and ventilator for more than 48 h were excluded from the analysis.

Statistical Analysis {#Sec5}
--------------------

Baseline demographics and comorbidities for each patient were reported using descriptive statistics expressed as counts and percentages for categorical data and mean ± standard deviation for continuous data. Primary and secondary outcomes were reported for LSG and LRYGB separately. Univariate analysis used Pearson *X*^2^ test or Fisher's exact test for categorical variables. Student's *t* test and analysis of variance were used for continuous variables. Statistical significance was set to *p* \< 0.05. Multivariable logistic regression was performed for each outcome and adjusted odds ratios (AOR) were reported. We adjusted for age, sex, race, ASA class, and BMI. Since several comorbidities may have functioned as mediating variables between diabetes status and outcomes, we did not adjust for them as this would have removed any indirect effects of DM. All analyses were performed using IBM SPSS version 25 (Armonk, NY).

Results {#Sec6}
=======

Patient Characteristics {#Sec7}
-----------------------

Of 336,927 patients, 73% were NDM, 18% NIDDM, and 9% IDDM (Table [1](#Tab1){ref-type="table"}). The cases performed were 244,840 (72.7%) LSG and 92,087 (27.3%) LRYGB. A majority in each group were white women with a mean BMI of about 45 kg/m^2^ and ASA class 3. Comorbidity rates significantly differed between groups, with the IDDM group showing the highest rates across almost all comorbidities, followed by NIDDM and NDM (Table [1](#Tab1){ref-type="table"}). LRYGB was performed with increasing frequency (and LSG with decreasing frequency) in the diabetic groups (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristics and comorbidities by diabetes mellitus statusPatient characteristicsNDM (*n* = 247,554)NIDDM (*n* = 60,012)IDDM (*n* = 29,361)*p* valueAge (years)43.2 ± 11.748.4 ± 11.452.3 ± 10.7\< 0.001SexFemale202,573 (81.8%)45,085 (75.1%)19,714 (67.1%)\< 0.001Male44,981 (18.2%)14,927 (24.9%)9647 (32.9%)RaceWhite198,031 (80.0%)47,540 (79.2%)23,349 (79.5%)\< 0.001African American46,734 (18.9%)11,515 (19.2%)5519 (18.8%)Other2789 (1.13%)957 (1.59%)493 (1.68%)ASA1--265,855 (26.6%)8491 (14.2%)2532 (8.62%)\< 0.0013175,405 (70.9%)48,891 (81.5%)24,441 (83.2%)4--56294 (2.54%)2630 (4.38%)2388 (8.13%)Body mass index (kg/m^2^)45.4 ± 7.8345.5 ± 8.2845.2 ± 8.12\< 0.001ComorbiditiesCoronary artery disease5227 (2.11%)2690 (4.48%)3290 (11.2%)\< 0.001Hypertension100,404 (40.6%)42,018 (70.0%)24,552 (83.6%)\< 0.001Hyperlipidemia37,493 (15.2%)26,694 (44.5%)18,979 (64.6%)\< 0.001Smoker21,985 (8.88%)5097 (8.49%)2253 (7.67%)\< 0.001COPD3199 (1.29%)1579 (2.63%)1256 (4.28%)\< 0.001Oxygen dependent1124 (0.45%)618 (1.03%)727 (2.48%)\< 0.001Obstructive sleep apnea86,149 (34.8%)28,303 (47.2%)15,705 (53.5%)\< 0.001Renal insufficiency742 (0.30%)334 (0.56%)1075 (3.66%)\< 0.001Dialysis434 (0.18%)97 (0.16%)440 (1.50%)\< 0.001Deep vein thrombosis3620 (1.46%)1100 (1.83%)835 (2.84%)\< 0.001History of pulmonary embolism2678 (1.08%)836 (1.39%)571 (1.94%)\< 0.001Anticoagulation5030 (2.03%)2052 (3.42%)1916 (6.53%)\< 0.001Inferior vena cava filter1654 (0.67%)529 (0.88%)396 (1.35%)\< 0.001Venous stasis2223 (0.90%)812 (1.35%)686 (2.34%)\< 0.001Chronic steroid use4072 (1.64%)1077 (1.79%)771 (2.63%)\< 0.001GERD73,323 (29.6%)21,567 (35.9%)11,767 (40.1%)\< 0.001Previous foregut surgery4145 (1.67%)837 (1.39%)460 (1.57%)\< 0.001Use of assistive device3034 (1.23%)1209 (2.01%)1200 (4.09%)\< 0.001Functional statusIndependent245,676 (99.2%)59,354 (98.9%)28,690 (97.7%)\< 0.001Partially dependent1097 (0.44%)463 (0.77%)539 (1.84%)Totally dependent781 (0.32%)195 (0.32%)132 (0.45%)Procedure performedLRYGB59,470 (24.0%)19,598 (32.7%)13,019 (44.3%)\< 0.001LSG188,084 (76.0%)40,414 (67.3%)16,342 (55.7%)*Abbreviations*: *ASA*, American Society of Anesthesiologists; *COPD*, chronic obstructive pulmonary disease; *GERD*, gastroesophageal reflux disease; *NDM*, non-diabetics; *NIDDM*, non-insulin-dependent diabetics; *IDDM*, insulin-dependent diabetics; *LSG*, laparoscopic sleeve gastrectomy; *LRYGB*, laparoscopic Roux-en-Y gastric bypassFrequency and percentage listed for categorical variablesMean ± standard deviation listed for continuous variables

Outcomes {#Sec8}
--------

Rates of primary and secondary outcomes were highest in the IDDM group, followed by NIDDM then NDM (Table [2](#Tab2){ref-type="table"}). For LSG, only VTE event rates did not differ based on diabetic status. For LRYGB, 30-day reoperation, septic events, urinary tract infections, and VTE events were not significantly different among the groups (Table [2](#Tab2){ref-type="table"}).Table 2Outcomes in diabetics versus non-diabetics for patients undergoing laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypassLSGLRYGBNDM (*n* = 188,084)NIDDM (*n* = 40,414)IDDM (*n* = 16,342)*p* valueNDM (*n* = 59,470)NIDDM (*n* = 19,598)IDDM (*n* = 13,019)*p* valuePrimary outcomes  Serious adverse events4947 (2.63%)1348 (3.34%)803 (4.91%)\< 0.0013570 (6.00%)1304 (6.65%)1127 (8.66%)\< 0.001  30-Day readmission5437 (2.89%)1195 (2.96%)816 (4.99%)\< 0.0013420 (5.75%)1093 (5.58%)914 (7.02%)\< 0.001  30-Day reoperation1460 (0.78%)370 (0.92%)199 (1.22%)\< 0.0011331 (2.24%)421 (2.15%)281 (2.16%)0.697  30-Day mortality75 (0.04%)36 (0.09%)25 (0.15%)\< 0.00159 (0.10%)27 (0.14%)31 (0.24%)\< 0.001Secondary outcomes  Length of stay \> 2 days14,678 (7.80%)3579 (8.86%)2152 (13.2%)\< 0.0019374 (15.8%)3289 (16.8%)2935 (22.5%)\< 0.001  Renal events132 (0.07%)54 (0.13%)66 (0.40%)\< 0.00195 (0.16%)45 (0.23%)80 (0.61%)\< 0.001  Cardiac events67 (0.04%)26 (0.06%)34 (0.21%)\< 0.00141 (0.07%)19 (0.10%)35 (0.27%)\< 0.001  Respiratory complications337 (0.18%)129 (0.32%)90 (0.55%)\< 0.001315 (0.53%)139 (0.71%)121 (0.93%)\< 0.001  Surgical site infection683 (0.36%)184 (0.46%)96 (0.59%)\< 0.001732 (1.23%)297 (1.52%)271 (2.08%)\< 0.001  Septic events158 (0.08%)42 (0.10%)30 (0.18%)\< 0.001166 (0.28%)50 (0.26%)44 (0.34%)0.374  Urinary tract infection501 (0.27%)123 (0.30%)72 (0.44%)\< 0.001294 (0.49%)93 (0.47%)81 (0.62%)0.135  VTE events916 (0.49%)220 (0.54%)89 (0.54%)0.236327 (0.55%)116 (0.59%)72 (0.55%)0.787  Transfusion intraoperatively/postoperatively (72 h)842 (0.45%)240 (0.59%)146 (0.89%)\< 0.001577 (0.97%)251 (1.28%)199 (1.53%)\< 0.001  Reinterventions1565 (0.83%)371 (0.92%)194 (1.19%)\< 0.0011490 (2.51%)434 (2.21%)354 (2.72%)0.011*Abbreviations*: *NDM*, non-diabetics; *NIDDM*, non-insulin-dependent diabetics; *IDDM*, insulin-dependent diabetics; *LSG*, laparoscopic sleeve gastrectomy; *LRYGB*, laparoscopic Roux-en-Y gastric bypass; *VTE*, venous thromboembolicFrequency and percentage listed for each variable

Multivariable analysis of patients who underwent LSG (with NDM patients as reference) showed higher 30-day mortality (NIDDM AOR = 1.52, *p* = 0.043; IDDM AOR = 1.91, *p* = 0.007) and risk of serious adverse events (NIDDM AOR = 1.15, *p* \< 0.001; IDDM AOR = 1.58, *p* \< 0.001) in the diabetic versus NDM groups (Table [3](#Tab3){ref-type="table"}). Multivariable analysis of patients who underwent LRYGB (with NDM patients as reference) showed higher risk of serious adverse events (NIDDM AOR = 1.09, *p* = 0.014; IDDM AOR = 1.43, *p* \< 0.001) in the diabetic versus NDM groups. In all diabetic cohorts except NIDDM in the LRYGB group, pulmonary embolism was the most common reported cause of the death followed by respiratory failure and infectious complications (Table [4](#Tab4){ref-type="table"}). Infectious complications were the most common cause of death in the LRYGB NIDDM group (Table [4](#Tab4){ref-type="table"}).Table 3Adjusted odds ratio for primary and secondary outcomes in patients undergoing laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass by diabetic statusLSGLRYGBNIDDMIDDMNIDDMIDDMAOR (95% CI)*p* valueAOR (95% CI)*p* valueAOR (95% CI)*p* valueAOR (95% CI)*p* valuePrimary outcomes  Serious adverse events1.15 (1.08--1.23)^a^\<0.0011.58 (1.46--1.71)^a^\< 0.0011.09 (1.02--1.16)^a^0.0141.43 (1.33--1.54)^a^\< 0.0011.38 (1.26--1.51)^b^\< 0.0011.32 (1.21--1.44)^b^\< 0.001  30-Day readmission1.00 (0.94--1.07)^a^0.9891.69 (1.56--1.83)^a^\< 0.0010.97 (0.90--1.04)^a^0.4211.26 (1.16--1.36)^a^\< 0.0011.68 (1.53--1.85)^b^\< 0.0011.30 (1.18--1.43)^b^\< 0.001  30-Day reoperation1.11 (0.99--1.25)^a^0.0721.40 (1.20--1.63)^a^\< 0.0010.91 (0.82--1.02)^a^0.1160.88 (0.77--1.01)^a^0.071.25 (1.05--1.49)^b^0.0130.97 (0.83--1.13)^b^0.66  30-Day mortality1.52 (1.01--2.28)^a^0.0431.91 (1.19--3.07)^a^0.0070.98 (0.61--1.55)^a^0.9181.32 (0.83--2.09)^a^0.2431.23 (0.73--2.08)^b^0.4321.33 (0.78--2.25)^b^0.295Secondary outcomes  Length of stay \> 2 days1.05 (1.01--1.09)^a^0.0231.52 (1.45--1.60)^a^\< 0.0011.00 (0.96--1.05)^a^0.9441.38 (1.32--1.45)^a^\< 0.0011.45 (1.36--1.53)^b^\< 0.0011.39 (1.32--1.47)^b^\< 0.001  Renal events1.27 (0.92--1.75)^a^0.1522.72 (1.98--3.72)^a^\< 0.0011.04 (0.72--1.49)^a^0.8442.22 (1.61--3.05)^a^\< 0.0012.24 (1.55--3.24)^b^\< 0.0012.25 (1.55--3.26)^b^\< 0.001  Cardiac events1.27 (0.80--2.02)^a^0.3053.12 (2.01--4.84)^a^\< 0.0010.96 (0.55--1.66)^a^0.8761.97 (1.21--3.20)^a^0.0062.42 (1.43--4.07)^b^0.0012.05 (1.16--3.62)^b^0.013  Respiratory complications1.41 (1.15--1.73)^a^0.0012.01 (1.57--2.56)^a^\< 0.0011.14 (0.93--1.40)^a^0.2021.34 (1.07--1.67)^a^0.011.41 (1.07--1.87)^b^0.0141.17 (0.91--1.50)^b^0.216  Surgical site infections1.19 (1.01--1.41)^a^0.0381.51 (1.21--1.88)^a^\< 0.0011.22 (1.06--1.40)^a^0.0051.71 (1.48--1.90)^a^\< 0.0011.35 (1.04--1.73)^b^0.0221.45 (1.22--1.71)^b^\< 0.001  Septic events1.05 (0.74--1.48)^a^0.7861.61 (1.07--2.42)^a^0.0230.78 (0.57--1.08)^a^0.1330.94 (0.66--1.33)^a^0.731.47 (0.91--2.37)^b^0.1191.25 (0.82--1.88)^b^0.296  Urinary tract infection1.10 (0.90--1.34)^a^0.3621.60 (1.24--2.07)^a^\< 0.0010.98 (0.77--1.24)^a^0.8411.33 (1.02--1.72)^a^0.0321.47 (1.09--1.98)^b^0.0121.33 (0.98--1.81)^b^0.063  VTE events1.05 (0.90--1.21)^a^0.5690.99 (0.79--1.24)^a^0.9310.97 (0.78--1.20)^a^0.7650.84 (0.65--1.10)^a^0.2150.96 (0.75--1.24)^b^0.7710.87 (0.65--1.18)^b^0.371  Transfusion intraoperative/postoperative (72 h)1.12 (0.97--1.30)^a^0.1211.45 (1.21--1.75)^a^\< 0.0011.24 (1.07--1.45)^a^0.0051.41 (1.19--1.67)^a^\< 0.0011.30 (1.05--1.60)^b^0.0161.16 (0.96--1.40)^b^0.133  Reintervention1.06 (0.95--1.19)^a^0.3131.33 (1.14--1.55)^a^\< 0.0010.91 (0.82--1.02)^a^0.0981.16 (1.03--1.32)^a^0.171.26 (1.06--1.51)^b^0.0111.27 (1.10--1.47)^b^0.001*Abbreviations*: *AOR*, adjusted odds ratio; *CI*, confidence interval; *NDM*, non-diabetics; *NIDDM*, non-insulin-dependent diabetics; *IDDM*, insulin-dependent diabetics; *LSG*, laparoscopic sleeve gastrectomy; *LRYGB*, laparoscopic Roux-en-Y gastric bypass; *VTE*, venous thromboembolicAdjusted odds ratios with 95% confidence intervals listed for each variable^a^Reference group of NDM^b^Reference group of NIDDMTable 4Cause of mortality in each diabetic patient cohort for laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypassCause of deathLSGLRYGBNDM (*n* = 75)NIDDM (*n* = 36)IDDM (*n* = 25)NDM (*n* = 59)NIDDM (*n* = 27)IDDM (*n* = 31)Pulmonary embolism18 (24.0%)6 (16.7%)5 (20.0%)9 (15.3%)1 (3.7%)6 (19.4%)Respiratory failure9 (12.0%)4 (11.1%)2 (8.0%)8 (13.6%)2 (7.4%)4 (12.9%)Infectious complications5 (6.7%)0 (0.0%)2 (8.0%)4 (6.8%)3 (11.1%)0 (0.0%)Anastomotic/staple line leak6 (8.0%)0 (0.0%)1 (4.0%)1 (1.7%)0 (0.0%)2 (6.5%)Intestinal obstruction0 (0.0%)0 (0.0%)0 (0.0%)3 (5.1%)2 (7.4%)0 (0.0%)Bleeding1 (1.3%)3 (8.3%)0 (0.0%)1 (1.7%)2 (7.4%)2 (6.5%)Other36 (48.0%)23 (63.9%)15 (60.0%)33 (55.9%)17 (63.0%)17 (54.8%)*Abbreviations*: *NDM*, non-diabetics; *NIDDM*, non-insulin-dependent diabetics; *IDDM*, insulin-dependent diabetics; *LSG*, laparoscopic sleeve gastrectomy; *LRYGB*, laparoscopic Roux-en-Y gastric bypassFrequency and percentage listed for each variable

Overall, IDDM patients had statistically higher odds for 13 of the 14 outcome measures when undergoing LSG and for 9 of 14 measures when undergoing LRYGB (Table [3](#Tab3){ref-type="table"}). The NIDDM patients showed statistically higher odds for 6 of 14 measures for LSG and 3 of 14 measures for LRYGB (Table [3](#Tab3){ref-type="table"}). When using NIDDM as the reference group, the IDDM patients showed statistically higher odds for 11 of 14 outcome measures when undergoing LSG and for 7 of 14 for LRYGB (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec9}
==========

This study aimed to compare the perioperative outcomes in diabetic patients undergoing LSG and LRYGB. Patients were stratified by insulin requirement into NIDDM and IDDM. The goal was to evaluate outcomes in IDDM. We hypothesized that these patients will have a higher complication rate as diabetic patients on insulin tend to have a longer duration of disease and, hence, higher rates of end organ damage. Our study found a higher 30-day perioperative morbidity in patients with diabetes compared with non-diabetics undergoing LSG or LRYGB. This was demonstrated independently in the NIDDM and IDDM groups. Patients with IDDM showed higher rates and higher adjusted odds for serious adverse events, readmission, length of stay, renal events, cardiac events, and surgical site infection for both LSG and LRYGB when compared with those of the NIDDM and NDM groups. As for mortality, IDDM and NIDDM patients had higher 30-day mortality when undergoing LSG but not LRYGB. This is, to our knowledge, the largest study comparing differences in perioperative complications between NIDDM and IDDM patients in bariatric surgery patients.

Although perioperative risk associated with DM has been studied in other surgical populations, differences between NIDDM and IDDM patients are not clearly defined \[[@CR10]\]. In a study on perioperative outcomes from the Michigan Surgical Quality Collaborative on 177,430 patients, Serio et al. found increased perioperative morbidity in general and vascular surgery patients with IDDM compared with that in NIDDM and NDM \[[@CR11]\]. However, their study did not show an increased risk of postoperative complications in NDDM patients \[[@CR11]\]. Similar to our findings, Steele et al. demonstrated in their study on 22,288 bariatric cases an increased risk of cardiac, infectious, and renal complications in diabetic patients although patients were not stratified based on insulin requirement status \[[@CR12]\]. Some studies have failed to demonstrate increased complications with LSG and LRYGB in diabetics \[[@CR8], [@CR9]\]. Nevertheless, these studies were smaller and likely underpowered.

Development of DM is a well-known side effect of obesity, with rates of both conditions rising every year in the USA according to the Centers for Disease Control and Prevention \[[@CR1], [@CR13]\]. For patients with obesity and DM, the comorbidities can be numerous and life-altering. The use of bariatric surgery for weight loss and reduction in obesity-related DM over a short period of time has been proven \[[@CR14]--[@CR16]\]. Several studies have shown data supporting the use of bariatric surgery for remission of DM \[[@CR17], [@CR18]\]. More recent studies clarified that bariatric surgery benefits specifically those patients with type 2 DM with more preoperative beta cell function \[[@CR19]\], both when measured in terms of serum insulin levels and as preoperative insulin requirements \[[@CR20]\]. However, the benefits appear to be mitigated in the obese with type 1 diabetes \[[@CR21]\], who almost universally require daily insulin supplementation.

Zaman et al. investigated perioperative glucose control in diabetics undergoing bariatric surgery and found that optimal control was predictive of long-term diabetes remission \[[@CR22]\]. It is unclear whether this was due to any physiological events perioperatively or simply due to worse disease manifesting as uncontrolled perioperative glucose levels. Leonetti et al. investigated the effects of specific preoperative diets in patients before bariatric surgery \[[@CR23]\]. Although results were inconclusive, positive or negative results could help answer whether perioperative glucose control has more to do with the perioperative adverse outcomes or another physiological mechanism is at play in diabetic patients. Nonetheless, bariatric surgery should continue to be offered to those with DM, but with a heightened awareness of potential perioperative complications as indicated by our study. Preoperative optimization of diabetes status may be of benefit to these patients to prevent adverse outcomes.

Our study had several limitations. The MBSAQIP database does not record data on perioperative blood glucose control which limits our ability to adjust for diabetic control, number of diabetic medications, or amount of insulin used. It may be possible that poor perioperative glucose control contributed to worse outcomes in IDDM. However, if this was the mechanism by which the perioperative risks are increased it would be helpful to identify and evaluate in future studies since this is an opportunity to intervene and prevent complications associated with DM. Moreover, patients who were not offered surgery due to poor preoperative glucose control were not included in the analysis as they never received surgery. This creates a selection bias in the study and may underestimate the perioperative risk involved. Furthermore, the database only includes 30-day postoperative data. Therefore, no long-term conclusion regarding complications or remission of diabetes can be drawn.

Conclusions {#Sec10}
===========

Perioperative morbidity in patients with DM undergoing bariatric surgery was higher than that in NDM patients, and 30-day mortality was higher in those undergoing LSG specifically. Patients with IDDM had increased risks of perioperative complications versus those with NIDDM. These observed increases in morbidity and mortality are real but modest in size and have to be considered against the real benefits of bariatric surgery in patients with obesity and DM.
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